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Tumour vasculature is notoriously sinusoidal and leaky, and is hence susceptible to vascular 24 
disruption. Microtubule destabilising drugs such as the combretastatins form the largest group of 25 
tumour vascular disrupting agents (VDAs) and cause selective shutdown of tumour blood flow within 26 
minutes to hours, leading to secondary tumour cell death. Targeting the tumour vasculature is a 27 
proven anticancer strategy but early treatment response bio-markers are required for personalising 28 
treatment planning. 29 
Protein induction following treatment with combretastatin A4-phosphate (CA4P) was examined in a 30 
mouse fibrosarcoma model (fs 188), where tumour cells express only the matrix-bound isoform of 31 
vascular endothelial growth factor A (VEGF188). These tumours are relatively resistant to vascular 32 
disruption by CA4P and hence a study of protein induction following treatment could yield insights 33 
into resistance mechanisms. 34 
The distribution of a number of proteins induced following treatment were visualised by MALDI-MSI. 35 
Responses identified were validated by LC-ESI-MS/MS and immunohistochemical (IHC) staining. 36 
Significant changes in proteins connected with necrosis, cell structure, cell survival and stress-37 
induced molecular chaperones were identified. Protein-protein interactions were identified using 38 
STRING 9.0 proteomic network software. These relationship pathways provided an insight into the 39 
activity of the active tumour milieu and a means of linking the identified proteins to their functional 40 
partners.  41 
 42 
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The identification of proteins that provide links to drug mechanisms and relate to  45 
sensitivity/resistance is essential for the progression of anti-cancer therapeutics. Early predictive bio-46 
markers for assessing efficacy of drug treatments are required for personalising cancer treatments. 47 
The identification of proteins induced after administration of an anti-cancer drug would provide 48 
valuable insights into drug treatment response mechanisms.  Treatment response is clearly complex 49 
and multifactorial but increased knowledge in this area could provide strategies for future 50 
combination therapies. A protein induction time course has been studied in a CA4P-treated mouse 51 
fibrosarcoma model. It is known that, shortly after administration of CA4P, major shutdown of the 52 
tumour vascular network occurs, leading to disruption of the 3D capillary architectural integrity [1].  53 
The aim of the proteomic study of regional tumour variations reported here was to advance 54 
understanding of tumour progression following treatment with CA4P, as a leading example of a VDA. 55 
We chose to use mouse fibrosarcomas that express only the matrix-bound isoform of VEGF (fs188), 56 
as these tumours are relatively resistant to CA4P, compared to their counterpart tumours that 57 
express the more soluble VEGF isoforms (VEGF120 and 164) [1]. Previously, we observed that 58 
proteomic studies of fs120 tumours (expressing only the soluble isoform of VEGF, VEGF120) were 59 
compromised by excessive masking of protein induction by very high haemoglobin levels, caused by 60 
extensive haemorrhage of the CA4P-sensitive blood vessels [2]. 61 
Matrix assisted laser desorption ionisation-mass spectrometry imaging (MALDI-MSI) is a unique 62 
technique that allows visualisation of the spatial distribution of a particular species, within a 63 
biological tissue sample. Multiple single mass spectra can be combined together to generate 64 
molecular maps of an ion of interest. MALDI-MSI has been frequently utilised for the direct protein 65 
profiling of tumour tissue samples, including tumour margin analysis [3-7]. A commonly used 66 
approach to study proteins of high relative molecular mass is the use of ‘‘on-tissue’’ tryptic digestion. 67 
This is a ‘bottom up’ proteomics approach, which enables the identification of proteins via the 68 


































































resulting tryptic peptides. This method is performed directly on cryo-sectioned tissue samples with 69 
the employment of MALDI-MSI. The Images generated reveal the positioning of peptides within the 70 
tryptically digested tumour sections [8, 5, 9]. 71 
 72 
Here we report the use of LC-ESI-/MS/MS label free quantification of proteins, in conjunction with 73 
MALDI-MSI, to study the pharmacodynamic response of mouse fibrosarcomas to the VDA, CA4P. The 74 
methodology employed tissue homogenisation, protein extraction, reduction, alkylation and 75 
enzymatic digestion of proteins prior to data-dependent LC/MS/MS analysis. The proteomic 76 
responses from fs188 tumours (saline-treated controls and tumours 0.5h, 6h, 24h and 72h post-77 
CA4P treatment) were used for LC-ESI-MS/MS and MALDI-MSI analysis, in order to create a time 78 
course of data, incorporating the vascular shut-down and tumour recovery phases post-drug 79 
administration.  80 
 81 
Materials and Methods 82 
Chemicals and Materials 83 
a-Cyano-4-hydroxycinnamic acid (CHCA), aniline (ANI), ethanol (EtOH), chloroform (CHCl3), 84 
acetonitrile (ACN), octyl-a/b-glucoside (OcGlc), tri-fluoroacetic acid (TFA), ammonium bicarbonate, 85 
haematoxylin, eosin, xylene and DPX mountant were from Sigma– Aldrich (Dorset, UK). Modified 86 
sequence grade trypsin (20 µg lyophilised) was obtained from Promega (Southampton, UK). 87 
 88 
Tissue samples 89 
All animal procedures were carried out in accordance with the United Kingdom Animals (Scientific 90 
Procedure) Act 1986, with local ethics committee approval and following published guidelines for 91 
the use of animals in cancer research (Workman et al., 2010). Mice were injected sub-cutaneously in 92 


































































the rear dorsum with a 50 µl tumour cell suspension containing 1 x  10
6
 fs188 tumour cells in serum-93 
free medium. These fibrosarcoma (fs) cells are engineered to express only the VEGF188 isoform of 94 
vascular endothelial growth factor A (VEGF) [1]. Tumours were allowed to grow to approximately 95 
500 mm
3
, before CA4P treatment (a 50 µl single dose of 100 mg/kg i.p in saline). Mice were 96 
sacrificed and tumours excised at various times after treatment before being snap frozen in liquid 97 
nitrogen-cooled isopentane and stored at -80°C for later processing. 98 
 99 
Experimental groups for Principle Component Analysis (PCA) and Partial Least Squares Discriminant 100 
Analysis (PLSDA) Controls (saline i.p), n = 4, CA4P (0.5 h after treatment), n = 5, CA4P (6 h after 101 
treatment), n = 5, CA4P (24 h after treatment), n = 5, CA4P (72 h after treatment) n = 4,. 102 
 103 
Tissue preparation 104 
10 µm-thick frozen tissue sections were cut, using a Leica CM3050 cryostat (Leica Microsystems, 105 
Milton Keynes, UK). The sections were then freeze-thaw mounted on poly-L-lysine glass slides. 106 
Mounted slides were either used immediately or stored in an airtight tube at -80 ⁰C for subsequent 107 
use. 108 
In situ tissue digestion and trypsin deposition 109 
The tissue samples were washed initially with 70% and then 90% ethanol for 1 min then left to dry. 110 
Subsequently, slides were immersed in chloroform for 10 s. Prior to matrix application, in situ tissue 111 
digestion was performed with trypsin solution prepared (from lyophilised trypsin), at 20 µg/ml, by 112 
addition of 50 mM ammonium bicarbonate (NH4HCO3) pH 8, containing 0.5%octyl-a/b-glucoside 113 
(OcGlc). 114 


































































The ‘‘Suncollect’’ (SunChrom, Friedrichsdorf, Germany) automatic pneumatic sprayer was used to 115 
spray trypsin in a series of layers. The sections for MALDI-MS and MALDI-MSI were incubated in a 116 
humidity chamber containing H2O 50%: methanol 50% overnight at 37⁰C and 5% CO2. 117 
 118 
Methods and instrumentation 119 
The matrix, α-cyano-4-hydroxycinnamic acid (CHCA) and aniline in acetonitrile:water:TFA (1:1:0.1 by 120 
volume), was applied using the Suncollect (at 5 mg/ml) in a series of 5 layers. For trypsin and CHCA,  121 
each layer was sprayed at 3µl/min.. Identical coordinate settings to those used for trypsin deposition 122 
were employed, to ensure sample uniformity. Equimolar amounts of aniline were added to the CHCA 123 
solution, i.e. 1 ml of 5 mg/ml CHCA solution contained 2.4 µl of aniline. 124 
MALDI- IMS/MS, MALDI- IMS/MSI and MALDI- IMS-MS/MS were performed using a HDMS SYNAPT™ 125 
G2 system (Waters Corporation, Manchester, UK) and Driftscope 2.1 software (Waters Corporation, 126 
UK). In order to achieve good quality MS/MS spectra, they were acquired manually moving the laser 127 
position and adjusting the collision energy to achieve good signal to noise for product ions across the 128 
full m/z range of the spectrum. Collision energies were adjusted from 70 to 100 eV during 129 
acquisition and acquisition times were generally of the order of 5–10 s per spectrum. MS/MS spectra 130 
were uploaded to perform a Mascot (Matrix Science, London, UK) search, which used the UniProt 131 
database in order to generate a sequence match. Image acquisition was performed using raster 132 
imaging mode at 30-100 µm spatial resolution, Biomap 3.7.5.5 software (http://www.maldi-133 
msi.org/) was used for image generation. To enable simple visual comparison between images all 134 
data were normalised to m/z 877/ m/z 1066 (peaks arising from the αCHCA matrix). 135 
LC-ESI-MS/MS analyses were performed with a Bruker nanoESI source fitted with a steel needle 136 
using Ion spray voltage of 1500V. MS/MS was acquired using the following AutoMSMS settings: MS: 137 
0.5 s (acquisition of survey spectrum), MS/MS (CID with N2 as collision gas): ion acquisition range: 138 


































































m/z 300-1,500, 0.1 s acquisition for precursor intensities above 100,000 counts, for signals of lower 139 
intensities down to 1,000 counts acquisition time increased linear to 1s, the collision energy and 140 
isolation width settings were automatically calculated using the Auto MSMS fragmentation table:, 5 141 
precursor ions, absolute threshold 1,000 counts, preferred charge states: 2 – 4, singly charged ions 142 
excluded. 1 MS/MS spectrum was acquired for each precursor and former target ions were excluded 143 
for 30 s. The data output was in the MASCOT (Matrix Science Ltd, Baker Street, London, UK) .dat file 144 
format. The .dat files selected used the following modification searches and parameters: 145 
Fixed modifiation: Carbamidomethyl (C) and variable modifications: Acetyl (Protein N-term),Gln-146 
>pyro-Glu (N-term Q),Glu->pyro-Glu (N-term E),Oxidation (M). 147 
 Massvalues: Monoisotopic, protein Mass: Unrestricted, peptide Mass Tolerance : ± 10 ppm, 148 
fragment Mass Tolerance: ± 0.1 Da and max Missed Cleavages   : 1 149 
The spectral data have been searched against the IPI mouse database (55272 sequences; 24903527 150 
residues, all data have been filtered to show only peptide matches with an expect value of 0.05 or 151 
lower.   152 
These data were then processed using Scaffold 4 (version 4.0.4) proteomic software tool for 153 
visualisation and analysis of the LC-ESI-MS/MS data (http://www.proteomesoftware.com/). The data 154 
files (.dat) produced from MASCOT, which corresponded to each digested analysed, were uploaded 155 
individually. Analysis with X! Tandem was selected in order to improve protein identifications with 156 
searching through an additional database. 157 
The following information includes the parameters and database and thresholds applied by Scaffold 158 
4 version 4.0.4; database employed was the ipi.MOUSE.v3.46 database, the number of proteins was 159 
55272, the search engine (as above) was MASCOT version 2.3.02. The fragment tolerance – 0.100 Da 160 
(monoisotopic), parent tolerance – 10.0 ppm (monoisotopic), fixed modifications - +57 on C 161 
(carbamidomethyl), variable modifications  were -18 on n (pyro-glu), -17 on n (pyro-cmC), +16 on M 162 


































































(oxidation) and +42 on n (acetyl). The maximum missed cleavages were 1. The peptide thresholds 163 
were 90% minimum and protein thresholds were 99% minimum, 2 peptides minimum.  164 
Statistical analysis 165 
Principle Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLSDA) were 166 
performed using MATLAB® (Matrix Laboratory) (MathWorks, Inc., Natick, MA 486 USA) in 167 
conjunction with the Eigenvector PLS_Toolbox. The PCA and PLSDA statistics are representative of 168 
the fs188 data using biological replicates (in triplicate) per time point with 6 technical replicates for 169 
each biological repeat i.e. 414 spectra in total.  170 
PCA and PLSDA data pre-processing using Waters MassLynx™ Software and MATLAB® 171 
Technical spectral replicates (6 per biological replicate) were selected from the MALDI-MSI 172 
chromatogram and MS results were then imported into MATLAB® in .txt format after application of 173 
“automatic peak detection” to achieve centroidal peak information using the instrument data 174 
processing software (Waters MassLynx™ Software). Normalisation (2‐Norm) and mean centre were 175 
selected and “contiguous blocks” was used for cross validation. 176 
Protein network analysis 177 
Accession lists generated by results from the LC-ESI-MS/MS Mascot searches were imported into the 178 
STRING 9.0 database. Observations of the relationships were made between the proteins identified 179 
throughout a fs188 time course. The sample data was used to build predictive proteomic pathways 180 
and study the predicted functional partners of known protein-protein interactions (http://string-181 
db.org/). 182 
Immunohistochemical staining 183 
Chemicals and Materials 184 
Methanol, acetone, hydrogen peroxide solution 30% wt., xylene, ethanol, Gill’s haematoxylin and 185 
DPX mountant were all purchased from Sigma Aldrich UK.  Phosphate buffer saline tablets (Dulbecco 186 


































































`A’ Tablets) were from Oxoid Ltd. Normal goat serum, ImmEdge hydrophobic barrier pen, 10X casein 187 
solution, avidin/biotin horseradish peroxidise complex blocking kit, ABC solution kit, 188 
diaminobenzidine (DAB) substrate kit  were from Vector Laboratories Ltd UK. Plectin antibody was 189 
from Abcam, Cambridge UK.  190 
 Immunohistochemical methods 191 
Mounted frozen tissue sections were allowed to equilibrate to room temperature for 5 minutes. 192 
Slides were then fixed in ice-cold acetone for 20 min then rinsed in PBS. Endogenous peroxidases 193 
were blocked using 30% H202 and methanol for 20 min. After rinsing in PBS, tissues were blocked for 194 
1hr using goat sera containing 10% casein. After PBS washes, Primary antibody (Ab) was added and 195 
left overnight at 4⁰C.  Primary antibody concentration was optimised using a range of dilutions (1:50 196 
- 1:1600). After overnight incubation and subsequent PBS washes, secondary Ab was added, diluted 197 
(1:200) in 2% goat sera and left for an incubation time of 1h at room temperature. After this period, 198 
ABC solution was added after rinsing in PBS and left to incubate for 45min at room temperature. 199 
After PBS washing, DAB solution was applied and left to allow development of the staining. Slides 200 
were rinsed in tap water prior to immersion in Gill’s haematoxylin for 2min. After slide dehydration 201 
using 70% - 100% EtOH, tissue was immersed in 2 changes of xylene for 5 min each. Slides were 202 
mounted using DPX mountant (Sigma Aldich, UK). 203 
Protein precipitation and digestion 204 
Chemicals and materials 205 
Chloroform (CHCl3), methanol (MeOH), acetonitrile (ACN), hydrochloric acid (HCl),  tri-fluoroacetic 206 
acid (TFA), ammonium bicarbonate, DL-Dithiothreitol solution, Iodoacetamide, urea, potassium di-207 
hydrogen phosphate (KH2PO4), TRIzol  were from Sigma–Aldrich (Dorset, UK). Modified sequence 208 
grade trypsin (20µg lyophilised) was obtained from Promega (Southampton, UK,). 209 


































































Tissue homogenisation and precipitation of protein 210 
The fs188 tumour tissue was homogenised in 800µl of TRIzol solution using a micro-homogeniser 211 
[10]. Homogenised solution was centrifuged (1,500 rpm) for 5 min to pellet out nuclei/ unbroken 212 
cells. Post-nuclear supernatant was then centrifuged (14,000 rpm) for 30 min. Resulting supernatant 213 
was discarded and cellular membrane pellet was retained for protein precipitation. 200µl of MeOH 214 
and 50µl of CHCl3 were then added to each protein pellet sample. After vortexing, 150µl HPLC H2O 215 
was added with further vortexing. After centrifugation (14,000 rpm) for 2 min, the bottom CHCl3 216 
layer was removed. A further 50µl CHCl3 was added, removal of the bottom CHCl3 layer was repeated 217 
following centrifugation (14,000 rpm) for 2 min. Subsequent removal of the H2O layer resulted in the 218 
remaining protein precipitate layer. CHCl3 (50µl) and MeOH (150µl) were added directly to the 219 
protein precipitate, after vortexing solution was centrifuged (14,000 rpm) for 2 min. Supernatant 220 
was removed and the protein pellet was then allowed to air dry for 2 min.  221 
Protein Digestion 222 
100µl of 0.1% RapiGest in 50mM NH4HCO3 buffer (pH 7.8) was added to the air-dried protein pellet. 223 
Each sample pellet/ solution was consecutively vortexed, incubated at -80⁰C (~ 1hr) and heated to 224 
70⁰C (1 min) until solubilised. Once fully solubilised the sample was heated to 100⁰C (2 min) and 225 
then left to reach room temperature. Each sample was reduced with dithiothreitol (DTT) (final 226 
concentration 5mM) for 30 min at 60⁰C the left to reach room temperature. Solutions were then 227 
alkylated with iodoacetamide (final concentration 15mM) in the dark for 30 min at room 228 
temperature. Sequence grade modified trypsin was added (20µg/ml) to 80µg of protein, following 229 
the BCA Protein Assay (see 3.3.9) used for protein determination. In-solution digests were incubated 230 
over night at 37⁰C with shaking. 231 
Preparation of samples for column loading 232 
HCl (final concentration 100mM) was added to the overnight fs188 digest. The solution was then 233 
incubated for a further 45 min at 37⁰C. The sample was then centrifuged (14,000 rpm, 4⁰C) for 10 234 


































































min and the supernatant removed for analysis. This remaining solution was lyophilised and stored at 235 
-80⁰C until further use. 236 
Protein estimation – BCA assay 237 
Chemicals and materials 238 
BCA protein assay reagent (bicinchoninic acid), copper (II) sulfate pentahydrate 4% solution, protein 239 
standard solution, 1.0 mg/mL bovine serum albumin (BSA) were from Sigma Aldrich UK. RapiGest 240 
detergent solution was purchased from Waters (UK). 241 
BCA method 242 
Solubilised protein pellets were thawed, vortexed and centrifuged ready for the BCA assay. BSA 243 
standards were prepared within an analytical range of 0-4 mg/ml. BCA reagent was added to BCA 244 
standards and tumour tissue solution samples and left to incubate at R/T for 30min. BCA standards 245 
were measured in triplicate and samples were measured in duplicate in a 96 well plate using a 246 
Wallac plate reader (spectrophotometer) at 570nm.  247 
Results and Discussion 248 
Figure 1 shows peptide mass fingerprints (as a summed spectrum from a representative tumour at 249 
each time point) from on tissue digestion of samples throughout the fs188 post CA-4P treatment 250 
time-course studied. The samples shown range from control/saline-treated to 72h post CA4P 251 
administration and were acquired using MALDI-IMS-MS. From a simple visual examination of the 252 
peptide mass fingerprints (Figure 1) identification of the changes occurring in the tumours following 253 
treatment with CA-4P is problematic.  However it would be expected that stress responses would be 254 
observed and to test this supposition, ion images corresponding to peptides arising from the 255 
digestion of stress response proteins were constructed. As an example of this the images in Figure 2 256 
(a) – (b) display a MALDI-MSI time course for a HSP-90 peptide at m/z 1168. The images for HSP-90 257 
indicate increased expression toward the 24h treatment, a response similar to the haemoglobin ion 258 


































































at m/z 1819.  These data indicate possible evidence of a ‘switch back to viability’ in the 72h post 259 
CA4P time point. 260 
In order to mine the data further Principle Component Analysis (PCA) and Partial Least Squares 261 
Discriminant Analysis (PLSDA) were employed to enable classification between each time point.  262 
The multivariate statistical technique of PCA was selected to provide an unbiased representation of 263 
the data generated from this proteomic response study, with PLSDA providing the element of 264 
discrimination allowing analysis between preselected time point results based on the PCA loadings 265 
plot outcome. Principle Component Analysis was employed to help determine groupings and 266 
similarities between the treatment time course data acquired via MALDI-MSI. The PCA in Figure 3(a) 267 
indicated the complex inter-grouping between tumour time points and replicates. Various sample 268 
groups share quadrants of the scores plot region with some groups positioned across two regions of 269 
the plot causing a merger between adjacent sample replicates. The loadings plot in Figure 3(b) did 270 
display separation of ions between plot regions with two ions relating to histone 2A and histone H3 271 
positioned in the area relating to the later time points. 272 
For PLSDA, 3 biological repeats per tumour time point were used, via MALDI-MSI acquisitions and 6 273 
technical spectral repeats were taken from each biological replicate.  Peak lists were exported from 274 
the instrument acquisition software and imported into MATLAB using the Eigenvector PLS_Toolbox. 275 
Predictive mathematical models were then built after selection of PLSDA, with the aim of observing 276 
any classification between tumour time-points. Figure 4 shows the classification between Control 277 
and 0.5h post-CA4P and Control and 24h post-CA4P respectively. Peaks corresponding to histone H3 278 
(m/z 1032) and actin (m/z 1198) appear to be the most obvious differences between the control and 279 
0.5h post CA4P PLSDA regression vector plots. Whereas in the control versus 24h post CA4P plot, 280 
additional peaks assigned to histone 2A (m/z 944) and haemoglobin (m/z 1274, m/z 1416 and m/z 281 
1529) are readily observable. 282 


































































The complexity of the whole sample cohort meant that no clear groupings were observable in the 283 
PCA scores plot (Figure 3a). The scores plot revealed various inter-grouping and sharing of the PCA 284 
score plot quadrants by the sample replicates indicating a need for further classification between 285 
sample groups. 286 
PLSDA models (Figure 4a) were built to compare the treatment time points against the control 287 
tumour tissue. 288 
There are numerous peaks in the low mass range seen here in the regression vector plots especially 289 
in the control tissue PLSDA vector plots. The peptide corresponding to actin was seen to increase in 290 
the 0.5h treatment. Kanthou and Tozer [18] showed that actin stress fibres developed in human 291 
umbilical vein endothelial cells at short times post CA4P administration. The results from this study 292 
showed an increase of filamentous actin over time after treatment, consistent with this finding. 293 
In the 24h post-treatment sample (Figure 4b), the appearance of the Hb peaks can be seen in the 294 
PLSDA regression vector plot. The actin peak remains increased in relation to the control vector plot 295 
with the same true for histone H3. Histone 2A is now also observed, possibly reflecting the 296 
occurrence of cellular necrosis and DNA damage as a result of CA4P administration.  297 
A link between increased tumour hypoxia (due to vascular shut-down) and histone H3 could be an 298 
explanation for the m/z 1032 peak observed in the regression vector plots of the fs188 tumour 299 
tissue [14].  300 
 301 
Figure 5 shows display the quantitative comparison of the expression of proteins showing response 302 
to treatment post-CA4P. The results shown here were selected from the many proteins identified 303 
using LC-ESI-MS/MS (n=1), based on their relevance to the cytoskeleton, their involvement in 304 
tumour stress response, or because they displayed a high percentage variability throughout the time 305 
course studied. These data were generated using normalised spectrum counts from the proteomic 306 


































































software tool Scaffold 4 version 4.0.4. The zoomed in region highlights the response given by the 307 
protein α-2 macroglobulin.  308 
 Table 1 details the proteins presented in Figure 5 displaying the protein accession number, number 309 
of unique peptides identified and % sequence coverage identified from MS/MS data generated.  310 
An example MS/MS spectrum of plectin, produced using Scaffold 4 software, is shown in Figure 6 311 
with corresponding normalised spectrum counts graph insert. A full optical scan is also featured of a 312 
72h plectin immunohistochemical tissue section, displaying the staining of the viable tumour tissue 313 
regions. The plectin MALDI-MSI time course of a peptide ion at m/z 977 shows the marked 314 
abundance of plectin in the Control/untreated tumour compared to the later time points. 315 
Quantitative analyses of structural and stress-related proteins identified in MALDI-MSI are shown in 316 
the label free normalised spectrum graph here in Figure 6. The proteins plectin and tubulin, involved 317 
in structural integrity, are decreased over time compared to stress proteins HSP-90 and GRP-78 that 318 
increase over time.   319 
The Scaffold 4 version 4.0.4 proteomics software tool was used for the analysis of the label free LC-320 
ESI-MS/MS time course experimental data. Time-course protein responses were plotted using 321 
normalised spectral counting calculated and presented via Scaffold 4 version 4.0.4. The rationale for 322 
selection of the proteins included in Figure 5 was to include proteins that either had a high 323 
percentage of co-variance throughout the time course i.e. ≥100%, provided a known validating 324 
response or were of relevance to the stress response in tumours. 325 
The increased abundance observed in Figure 5 for both haemoglobin subunit alpha and haemoglobin 326 
subunit beta-2 is indicative of the distinctive gross pharmacological response arising from the 327 
administration of a vascular disrupting agent i.e haemorrhagic necrosis.  328 
Heat shock protein 90 (HSP-90) is ubiquitous in all normally functioning cells and serves to prevent 329 
the misfolding of proteins by helping to retain the correct structural format of the protein [15]. HSP-330 


































































90 has been suggested as a potential target protein for anticancer therapy due to the cancer cell’s 331 
dependence on this protein for structural conformity [16]. It is known that inhibition of HSP-90 332 
results in the degradation of the HSP-90 stabilised protein (client protein) via the proteasome.  333 
Elevated levels of HSP-90 in breast cancer patients have been found to correlate with poor patient 334 
survival due to the conserving effect of HSP-90 on human epidermal growth factor receptor 2 [17]. 335 
HSP-90 is commonly highly expressed in solid tumours and plays a key role in the evasion of 336 
apoptosis thus promoting tumour cell survival [16]. The presence of HSP-90 is shown throughout the 337 
MALDI-MSI fs188 time course in Figure 2 and label free normalised spectrum counts graph in Figure 338 
5. The MALDI image corresponding to 24hr post-CA4P (Figure 2) indicates very high levels of HSP-90 339 
at this time, suggesting a protective role against protein misfolding during recovery. The possible 340 
‘switch back to viable tissue’ appears to be exhibited by the MALDI-MSI 72h time point in Figure 2a 341 
and b as a reduction in HSP90 and Hb expression.  342 
The data shown in Figure 5 also demonstrates the disruption in the architectural integrity of the 343 
vasculature as indicated by decreases in structural tubulin beta-5 chain and tubulin alpha-1B chain 344 
compared to the control tumour tissue.  345 
Actin, cytoplasmic 1(Beta-actin) and actin, alpha skeletal muscle precursor (Alpha-actin-1) appear to 346 
show different trends throughout the LC-ESI-MS/MS data (Figure 5). It is known that the 347 
reorganisation and/or disruption of the cytoskeleton results in stress fibre formation [18] that could 348 
explain an increase in beta-actin in the 0.5h time point (Figure 5) in response to the drug.  Over time, 349 
the tumour appears to recover, favouring actin polymerisation after a brief decrease of beta-actin in 350 
the 6h time point, with increased levels evident at  24h and 72h post CA4P administration.  351 
The role of progenitor cells and/or infiltrating immune cells in tumour response to treatment is 352 
receiving a great deal of attention. Recently, it was shown that a Tie-2 expressing sub-population of 353 
macrophages was increased after CA4P treatment, in two mouse models of breast cancer [19] and 354 


































































that these contributed to resistance to CA4P treatment. Alpha-2-macroglobulin is known to be 355 
synthesised locally in tissues by infiltrating macrophages.   It is a carrier protein and is also known to 356 
be linked to growth factors and cytokines i.e. basic fibroblast growth factor, Interleukin 1- β (IL-1β) 357 
and transforming growth factor beta [20, 21].  358 
The dose response relationship of alpha-2-macroglobulin from the LC-ESI-MS/MS results can be 359 
observed in the Figure 5 insert. Alpha-2-macroglobulin was not detected in the early fs188 treated 360 
time points but a sudden increase is evident from 6 hours, with a surge at the 24h time point and 361 
then a drop in expression at 72 hours (Figure 5). Alpha-2-macroglobulin levels may reflect numbers 362 
of infiltrating immune cells. However, attempts to validate this possibility by immunohistochemical 363 
staining for the macrophage cell surface marker, F4/80, were inconclusive due to inter-tumour 364 
variability in staining levels (results not shown). The steep increase of alpha-2-macroglobulin at 24h, 365 
followed by a decrease at 72 h, follows the pattern of increased and resolving tumour necrosis, 366 
found at these time-points, and may relate to phagocytic activity of the macrophage tumour 367 
population.  368 
Plectin (Figure 5 and 6) was found to have a high value of percentage co-variance (170%) of response 369 
throughout the sample time-course. LC-ESI-MS/MS data (Figure 5) indicated a marked abundance of 370 
plectin in the untreated tumours and decreased levels by 0.5 h after CA4P treatment, with very low 371 
levels thereafter. The MALDI-MSI data for plectin showed a very similar pattern (Figure 6). As further 372 
confirmation of this response, immunohistochemical studies using a plectin antibody were 373 
performed to determine the expression in histological tumour sections. The plectin staining 374 
suggested that this protein is highly expressed in untreated fs 188 tumours. This agreed with both 375 
the MALDI-MSI and LC-ESI-MS/MS data. From the plectin immunohistochemistry performed it is also 376 
apparent that plectin is distributed only in viable tumour regions.  377 
Plectin has been proposed as a novel prognostic marker for head and neck squamous cell carcinoma, 378 
linked to roles in cancer cell migration and invasion (Katada et al (2012). Elevated levels of plectin 379 


































































have also been found in colorectal cancer, prostate cancer and pancreatic ductal adenocarcinoma 380 
[24-27]. Results reported here suggest that CA4P greatly interferes with plectin expression. However, 381 
further investigations are warranted to determine whether changes in plectin levels are simply 382 
reflecting changes in necrosis following treatment or whether there are significantly different levels 383 
in surviving viable tumour regions. 384 
IQGAP1 is a multimodal scaffolding protein that is implemented in actin dynamics, tubulin 385 
multimerisation, cell motility and migration, via numerous signalling pathways [28]. Some studies 386 
reported that increased expression of IQGAP1 resulted in disruption of cell-cell junctions thus 387 
promoting a migratory, invasive phenotype [29]. We have demonstrated that IQGAP1 is undetected 388 
in untreated fs188 fibrosarcomas  (Figure 3) but is visible from 0.5h  post CA-4-P treatment, at which 389 
point levels decrease through to the 72h treatment group, suggesting possible CA4P 390 
pharmacological action.  391 
The glycoprotein Tenascin (C), has similar functions to those of IQGAP1 having involvement in 392 
tumour survival and the outgrowth of circulating cancer cells [30]. The levels of tenascin C we 393 
observed (Figure 5) show an increase in the 0.5h treatment group compared to untreated controls 394 
with decreases evident in the later time points post CA-4-P administration, a similar response to that 395 
observed for IQGAP1. The action of CA4P does appear to have an inhibitory effect on Tenascin C. 396 
However, it has been suggested that its fellow glycoprotein, Tenascin W, is more specific for 397 
tumours [31]. Mass spectrometric techniques could help to ascertain the relative abundance of 398 
these two proteins in tumour tissue and their response to treatment. 399 
Alpha-enolase is thought to be implemented in many processes. In addition to its role as a glycolytic 400 
enzyme it is known to have transcriptional capacity and molecular chaperone capabilities with 401 
hypoxia being a known modulator of its expression [32-34]. CA4P treatment caused a steady 402 
increase in alpha-enolase with time. Alpha-enolase is regarded as a tumour-associated antigen (TAA) 403 
and when elevated levels are present in tumour tissue, activation of immune responses occurs in 404 


































































patients with cancer [35]. Increased expression of Alpha-enolase is also indicative of aggressive 405 
tumour progression. Therefore, an increase in alpha-enolase after CA4P (Figure 5) could be a marker 406 
for the resistant phenotype of the fs188 tumour type, reflecting its regenerative capability.  407 
From the LC-ESI-MS/MS time-course results in Figure 5, Tgfbi is shown to demonstrate a ‘L’ shape 408 
trend line similar to that seen for plectin (Figure 5 and 6), with high levels in untreated compared to 409 
treated tumours.  The latter response is a trend similar to the results documented in an article by Li 410 
et al (2012) [36]. Tgfbi may have a dual role; an anti-tumourigenic function in early tumour growth 411 
and as a pro-oncogenic supporter in late stage tumours. Therefore the significance of the CA4P-412 
induced changes shown in our study remains to be determined.  413 
Figure 7 shows the immunohistochemical staining of plectin in the fibrosarcoma tissue in 414 
Control/untreated (Figure 7a), 6h (Figure 7b) and 24h (Figure 7c) post CA4P. The staining for plectin 415 
in the untreated tissue is widely spread and intense throughout the tissue. The emergence of 416 
necrotic tissue is observable in the 6h anti-plectin (and insert) image with increased necrosis visible 417 
in the 24h post CA4P section. Plectin however, appears in the viable tissue region located in the 418 
tumour periphery of the fibrosarcoma tissue. Plectin is decribed as a ‘cytolinker’ and has a key role 419 
in the stabilisation of the cytoskeleton via the formation of a mesh-like scaffold [12,. 13].  420 
 The proteomic pathway tool String 9.0 was used to depict the relationships between proteins 421 
featured earlier. Figure 8 shows direct links between proteomic ‘bubbles’ and spatial associations, 422 
propose an understanding of functionality between the proteins within the network.  423 
The MALDI peptide mass fingerprints (Figure 1) from the fs188 on tissue digests contain numerous 424 
peaks. The challenge here was the exploration and identification of the low abundant species 425 
present. The MALDI images in Figure 2 are examples of how the spatial distribution and ion 426 
intensities can differ greatly across the treatment time course.  427 
 428 


































































Visualisation of the complex protein pathways and networks that govern tumour biological function 429 
helps the understanding of protein dose response relationships. String 9.0 (http://string-db.org/) 430 
was used to visualise protein-protein interactions in the data reported here.  Protein-protein 431 
interactions visualised by String 9.0, are depicted by spatial positioning and linear connections with 432 
thicker lines representing stronger associations between proteins. The focal pathway association 433 
seen here (Figure 8) within this group of proteins is the linkage between the heat shock proteins; 434 
HSP-90α, HSP-90β, GRP-78 (Hspa5) and Actin, cytoplasmic 1 and Ras GTPase-activating-like protein 435 
(IQGAP1). The stronger association within this pathway runs directly from HSP-90α through to 436 
IQGAP1 encompassing Actin, cytoplasmic 1. The latter is characteristic of an active tumour micro-437 
environment incorporating the morphological changes exhibited by architectural remodelling of 438 
actin due to CA4P administration. Although not directly linked, plectin and tenascin display close 439 
positioning to IQGAP1, all of which as previously mentioned, are known to be involved with 440 
promoting tumour survival, cellular migration and metastatic invasion.  A strong link is visible 441 
between fellow tubulin proteins. Interestingly, alpha-enolase (ALO22784) is in close proximity to 442 
carrier protein alpha-2-macroglobulin (A2m). Close positioning of ALO22784 to macrophage related 443 
protein A2m is indicative of allergic stress response, which remains true to the pharmacological 444 
intervention here post CA4P administration [40]. Haemoglobin subunit beta positioned above (A2m 445 
and ALO22784) supports the haemorrhagic action of CA-4-P. Tumour suppressing adhesion protein 446 
transforming growth factor-beta-induced protein ig-h3 (Tgfbi), is joined in this structural 447 
reorganisational milieu. As mentioned above, this protein is involved in cell-collagen interactions. 448 
The data reported here shows an active tumour response to CA4P. Collectively, the results from the 449 
LC-ESI-MS/MS comprise of proteins connected with necrosis, cell structural reorganisation and actin 450 
polymerisation but also tumour survival and stress-induced molecular chaperones. The inverse 451 
correlation of molecular chaperone HSP-90 and survival-promoting plectin is evidence of this. The 452 
gross changes in expression were detectable by LC-ESI-MS/MS, with the distinct regional differences 453 
in the tissue being observable in the MALDI-MSI and immunohistochemistry data. 454 


































































Overall the levels of the proteins involved in stress responses i.e. GRP-78, HSP-90β, HSP-70 are 455 
increased over time, but interestingly expression of HSP-90α was reduced in the 72h treatment 456 
sample, possibly highlighting the switch back to tumour viability in this stage post-CA4P 457 
administration, as can be seen from viable tissue regeneration in histological sections. The latter 458 
may be a reflection of another tumour cell population surpassing the protective role of HSP-90 459 
resulting in tumour rejuvenation. For the future, it will be important to examine potentially subtle 460 
proteomic differences between untreated viable and regenerating viable tumour regions.   461 
Concluding Remarks 462 
A combination of MALDI-MSI, LC/MS/MS and IHC has been used to study protein induction in a 463 
mouse fibrosarcoma model following treatment with CA4P, a vascular disrupting agent.   Analysis of 464 
the MALDI-MSI data by multivariate statistics revealed gross changes in protein response indicative 465 
of stress and necrotic haemorrhaging. These findings were validated by the LC/MS/MS and IHC data. 466 
Analysis of the LC/MS/MS data also revealed changes in expression of other cancer significant 467 
proteins e.g. plectin and HSP90. It was possible to then plot images of peptides of these proteins 468 
within the original MALDI-MSI data set to demonstrate their regional distribution.  An inverse 469 
correlation between the expression of structural and stress response proteins over the time-course 470 
experiment was observed and proteins that distinguished the viable tumour region were identified. 471 
The use of multiple technologies to validate the findings was found to be essential for confidence in 472 
MALDI-MSI data. 473 
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Table and Figure Legends 635 
Figure 1: Examples of MALDI Peptide Mass Fingerprints (PMFs) from a time course study. Spectra 636 
shown are Saline (Control), 0.5h, 6h, 24h and 72h post CA4P treatment of fs188 mouse 637 
fibrosarcomas.  638 
Figure 2: MALDI-MSI time course images and zoomed in mass spectra of peptides corresponding to 639 
(a) HSP-90 at m/z 1168 and (b) haemoglobin at m/z 1819. The tumour tissue images here show the 640 
spatial distribution of the selected ions in Control, 0.5h, 6h, 24h and 72h post CA4P treatment 641 
samples. The possible switch back to viable tissue is indicated by the red arrow in the 72h sample   642 
and asterisks mark the ions of interest in each zoomed spectrum 643 
Figure 3: Principle Component Analysis (a) scores plot displaying the complex groupings and inter-644 
grouping between the full sample time course replicates, colour coded icons are as follows:  6 - 645 
Control groups, 7 – 0.5h, 8 – 6h, 9 – 24h and  10 – 72h post CA4P. (b) corresponding loadings plot 646 
displaying the spatial relation of each ion to the position of groupings in the scores plot (a). The two 647 
arrows indicate histones 2A and H3, commonly observed in the PCA scores region relating to the 648 
later time points possibly reflecting necrosis/apoptosis in the tumour tissue. 649 
Figure 4: Partial least squares discriminant analysis (PLSDA) regression vector plot comparing MALDI 650 
“on-tissue” digest data from samples of fs188 Control and 0.5h post combretastatin-4-phosphate 651 
(CA4P), and Control and 24h post CA4P fs188 on-tissue digests. The blue arrows are indicative of 652 
Histone 2A (m/z 944), Histone H3 (m/z 1032), Actin (m/z 1198) and the red arrows correspond to Hb 653 
peaks; m/z 1274, m/z 1416 and m/z 1529. 654 
Figure 5: A selection of fs188 time course results post CA4P treatment using LC-ESI-MS/MS. The 655 
rationale for protein selection here were targets that were either relevant to the tumour stress 656 
response or displayed a high percentage of normalised spectrum count variability  throughout the 657 


































































treatment time course after importing into proteomic software tool Scaffold. The zoomed in insert is 658 
to show the response by α-2 macroglobulin.  The result shown are n = 1. 659 
Figure 6: Example MS/MS spectrum and insert showing a normalised intensity graph of plectin in 660 
f188 LC-ESI-MS/MS results. A full optical scan showing the staining of Plectin in the viable tumour 661 
tissue region. MALDI-MSI time course displays the intensity of plectin at m/z 977 throughout the 662 
treatment points; control, 0.5h post CA4P, 6h post CA4P, 24h post CA4P and 72h post CA4P. Label 663 
free graph of normalised spectrum counts to show an inverse relationship between structural 664 
proteins and those thought to be involved in tumour survival and the stress response. 665 
Figure 7: Immunohistochemical staining of Plectin in Fs188 tissue post CA4P treatment.  The 666 
following examples shown are part of a CA4P time course studied. (a) plectin staining of Control 667 
untreated fs188 tissue, the staining is diffuse throughout the tissue here, (b) plectin staining of fs188 668 
tissue 6h post CA4P treatment; at higher magnification the staining of viable tissue is clearly defined 669 
in comparison to the unstained necrotic tissue, (c) plectin staining is shown to be localised in a viable 670 
tissue region near the tumour edge of 188 fibrosarcoma after 24 hours CA4P  treatment.  671 
Figure 8: LC-ESI-MS/MS selected proteins of interest from fs188 tumours shown in Figure 5, 672 
visualised through proteomic pathway software STRING 9.0. The interactions shown here depict 673 
direct (physical) and indirect (functional) links between the proteins that were identified from 674 
tryptically digested tissue homogenate. 675 
 676 
Table 1: Table of protein identifications detailing protein accession number, number of unique (in 677 
terms of amino acid sequence) peptides identified and % sequence coverage identified from MS/MS 678 
data generated.  679 
 680 
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